Diabetic Nephropathy Market Size, Share, and Growth Forecast for 2025 - 2032

The global diabetic nephropathy market is estimated to reach a size of US$ 3.7 Bn in 2025. It is predicted to rise at a CAGR of 7.3% through the assessment period to attain a value of US$ 6.2 Bn by 2032.

Rising incidence of diabetes is fueling the global healthcare industry because of diabetic nephropathy, a serious diabetes complication that causes kidney damage and proteinuria. According to the International Diabetes Federation, the number of diabetes cases is projected to increase from 415 million in 2015 to 642 million by 2040, with Europe and the Western Pacific accounting for the highest numbers.

The global pandemic disrupted clinical trials and pharmaceutical supply chains, in China and India, which host 40% of drug manufacturing sites, causing temporary shortages. After the market rebound, several pharma institutes are estimated to extend their product inventory. For instance,

• In October 2023, AstraZeneca broadened its Farxiga studies to assess its effectiveness in diabetic nephropathy after the FDA approved it for chronic kidney disease.
• In November 2023, Boehringer Ingelheim revealed that it was developing an SGLT2 inhibitor to treat diabetic kidney disease in its early stages.

Key Highlights of the Markets

• Increasing prevalence of diabetes is leading to a direct rise in diabetic nephropathy cases, especially in aging populations.
• The awareness of early screening and diagnosis is vital for improved disease management and treatment initiation.
• Creation of innovative therapeutic strategies that target specific disease pathways can enhance the efficacy of treatment.

• Growing research in biomarkers for early detection is opening up new diagnostic market opportunities.
• In 2025, angiotensin-converting enzyme inhibitors are estimated to attain a market share of 30% due to its quick effectiveness.
• Based on route of administration, oral segment is projected to account for a market share of 58% in 2025 due to its effectiveness in patient care.
• North America's market share is predicted to reach 35% in 2025 due to developments in healthcare infrastructure.
• Europe is anticipated to hold a market share of 28.7% in 2025 with rising CKD prevalence in the region.

North America is likely to dominate the global diabetic nephropathy market, accounting for 35% of the share by 2025, with a projected CAGR of 5.6% from 2025 to 2032. For instance,

• According to the CDC, over 37.3 million Americans had diabetes in 2023, with diabetic nephropathy being one of the most common and severe complications.

The region’s robust healthcare infrastructure, high healthcare expenditure, and advanced diagnostic tools contribute to its market leadership. For example,

• In October 2023, Eli Lilly expanded its clinical trials for Jardiance (empagliflozin) in diabetic nephropathy patients across the U.S., focusing on preventing kidney disease progression.
• In November 2023, AstraZeneca introduced Farxiga's expanded indications, focusing on early intervention in kidney complications.

Europe's diabetic nephropathy market is set to dominate the global market by generating 28.7% share in 2025. This is largely due to its high prevalence of diabetes, obesity, and related complications, including chronic kidney disease. For instance,

• According to the International Diabetes Federation, over 61 million Europeans lived with diabetes in 2023, contributing to rising demand for therapeutic drugs.
• In October 2023, Novo Nordisk launched clinical trials for a new GLP-1 receptor agonist targeting CKD progression in diabetic patients across Europe.
• In November 2023, Boehringer Ingelheim launched an extended Jardiance study with an emphasis on treating early-stage nephropathy.

Increased healthcare spending and early detection methods, together with Europe's extensive healthcare systems and greater emphasis on controlling comorbidities, are fueling the need for nephropathy medications. 

In 2025, angiotensin-converting enzyme inhibitors are anticipated to account for 30% of the market, mainly because of their use in the treatment of diabetic nephropathy. In diabetic patients, these drugs decrease the course of kidney damage by relaxing blood arteries and lowering blood pressure.

Because of their cost and effectiveness, ACE inhibitors continue to be a mainstay treatment even in the face of the emergence of more recent medication classes like SGLT2 inhibitors. Pfizer and AstraZeneca have strengthened their position in the diabetic nephropathy therapy industry by extending the availability of Ramipril to underprivileged areas.

In 2025, oral administration is predicted to account for 58% of diabetic nephropathy treatment industry share, due to its convenience, ease of use, and reduced risks. Oral drugs, primarily absorbed in the small intestine, ensure improved bioavailability, crucial for managing chronic conditions like diabetic nephropathy. For instance,

• In October 2023, Boehringer Ingelheim introduced an oral SGLT2 inhibitor designed to prevent kidney disease progression in diabetic patients, highlighting the ongoing advancements in this delivery method.
• AstraZeneca launched an updated oral formulation of Farxiga in November 2023, focusing on enhanced patient compliance.

Patients and healthcare professionals frequently choose oral administration since it effectively raises insulin portal levels, lowers the risk of skin infections, and minimizes adverse effects.

Globally, diabetes prevalence is increasing, leading to a surge in diabetic nephropathy cases, with early screening campaigns and increased healthcare expenditure enhancing disease management. For instance,

• According to the International Diabetes Federation, diabetes cases are expected to rise to 642 million by 2040. Combination therapies, such as those combining SGLT2 inhibitors with RAAS blockers, are gaining traction for their effectiveness in managing diabetic nephropathy.

• In October 2023, Eli Lilly announced new clinical trials for a combination therapy involving Jardiance (empagliflozin) and a novel biomarker-based detection tool.
• In November 2023, AstraZeneca initiated a research program focusing on AI-driven diagnostic tools for early nephropathy detection.

In addition to improving affordability, raising market competition, and impacting pricing tactics, the emergence of generic drugs, lifestyle changes, and sophisticated diagnostic technologies is increasing demand for specialized therapies.

The global diabetic nephropathy market recorded a CAGR of 6.5% in the historical period from 2019 to 2023. New diabetic drugs approved by the FDA in underdeveloped nations are opening up new markets. To reduce the risk of ESRD, deteriorating renal function, cardiovascular mortality, and heart failure hospitalization in people with type 2 diabetes and DKD, for instance, the SGLT2 inhibitor canagliflozin was authorized in 2019.

• The comparable application for empagliflozin tablets, registered under the brand name Jardiance, was approved by the US FDA in 2023.
• A promising treatment for type-2 diabetes and chronic kidney disease is Bayer's finerenone, which was launched in India in 2022.

Demand for diabetic nephropathy is estimated to record a considerable CAGR of 7.3% during the forecast period between 2025 and 2032.

Upsurge in Diabetes Cases to Push Demand in Healthcare Sector

On a global scale, the case of diabetes is envisioned to fuel demand for different therapies. The common indication of diabetic nephropathy is diabetes mellitus; individuals with this illness are ten times more likely to get end-stage renal failure, which increases the need for angiotensin-converting enzyme inhibitors. For example,

• The International Diabetes Federation reported a 15% increase in diabetic nephropathy cases worldwide in 2024, with AstraZeneca's targeted therapy program launching after successful Phase III trials.
• Growing patient population has led to increased healthcare spending, with key health systems reporting a 25% rise in nephrology department budgets.

The global diabetic kidney disease market is driven by increasing incidence of diabetes and the geriatric population. The number of people with diabetes is projected to rise from 415 million in 2015 to 642 million by 2040. Advances in treatment and increased awareness about diabetic kidney disease diagnosis and management are expected to provide lucrative growth opportunities for market players.

Progression in Diagnostic Procedures to Present Novel Avenues

The industry is estimated to bloom with the development of innovative therapies for diabetes cure. For example,

• The FDA hastened its analysis and expanded research and development spending in diabetic nephropathy after a March 2024 study showed that a novel class of drugs that target kidney inflammation in diabetes patients was successful.

The advancement in diagnostic procedures is anticipated to fuel the research and development practices in the healthcare sector. The diagnostic category was driven by Roche's introduction of a new biomarker panel in February 2024, which increased diagnosis rates by 40% and was widely adopted in major medical facilities.

High Medical Expenses Affects the Patient Care Industry

The cost of the therapies for patient care and research and development for the novel solutions are estimated to be high.

• According to a healthcare cost analysis, the cost of treating diabetic nephropathy has increased by 35% in the last 12 months, which has limited market penetration in developing nations and impacted patient access to innovative treatments.

A survey found that 40% of patients do not adhere to their treatment programs, which affects the market expansion and care efficacy. As a result, developing efficient treatment programs and combination medications is being given increased importance.

Development in Targeted Therapies for Personalized Medication Opens Fresh Avenues      

The development of targeted therapeutics and personalized medicine is transforming diabetic nephropathy therapy by delivering precise, effective interventions based on patient-specific data such as genetic markers and biomarkers, resulting in better results.

Since hospital pharmacies continue to be the major distribution channel for cutting-edge treatments, the need for diabetic nephropathy is anticipated to expand globally, with a 52.3% market share in 2025. For example,

• In October 2023, Boehringer Ingelheim launched a clinical trial for BI 7905, a targeted therapy designed to slow kidney disease progression in diabetic patients.
• In November 2023, AstraZeneca announced an expansion of its Farxiga portfolio, integrating AI-based tools to identify patients likely to benefit from personalized regimens.

Increased research and development investments in precision medicine are revolutionizing the management of diabetic nephropathy.

Novel Research in Biomarkers for Early Detection to Create Growth Prospects     

The research into the use of biomarkers for diabetic nephropathy early detection is expanding diagnostic possibilities, enabling earlier treatment and better patient outcomes. The potential of biomarkers such as albuminuria, serum creatinine, and genetic markers is being investigated. For instance,

• In October 2023, Abbott Laboratories introduced a diagnostic assay using novel biomarkers for early detection of nephropathy, targeting primary care and specialized clinics.
• In November 2023, Roche Diagnostics announced a partnership with academic institutions to develop a biomarker panel for chronic kidney disease screening.

Such initiatives align with the growing demand for personalized healthcare solutions, aiming to improve disease monitoring and facilitate timely, targeted therapeutic interventions in diabetic nephropathy care.

The global diabetic nephropathy industry is experiencing a surge of investment focused on the research and development of groundbreaking medications. Manufacturers are placing a strong emphasis on producing high-quality, essential healthcare products that can improve patient outcomes.

To enhance their market presence, some companies are strategically pursuing alliances and mergers, creating stronger networks and resources in the field. Emerging start-ups are poised to introduce innovative solutions that promise to reshape and support the industry in addressing the challenges associated with diabetic nephropathy.

Recent Industry Developments

• In November 2024, Thiruvananthapuram launched a year-long diabetes action plan, trained doctors and health workers, and hosted an international seminar in January 2025.
• In May 2024, AstraZeneca developed a new app for primary care physicians to manage chronic kidney disease (CKD) and predict kidney failure risk, partnering with various medical organizations to promote early detection and intervention.
• In February 2024, Simple HealthKit introduced a kidney disease testing program to improve health plans' performance, focusing on hard-to-reach members and HEDIS and Medicare Advantage star ratings.
• In November 2023, ProKidney Corp. received approval from the U.K. MHRA for proact 1 (REGEN-006) and scientific advice from the EMA for phase 3 protocols for REACT in diabetic chronic kidney disease.
• In September 2023, the U.S. FDA approved Jardiance, a 10mg tablet, to reduce kidney disease progression and cardiovascular death in CKD patients, but not those with type 1 diabetes, polycystic kidney disease, immunosuppressive therapy, or empagliflozin hypersensitivity.